Pfizer Inc. (NYSE:PFE) Shares Bought by Community Trust & Investment Co.

Community Trust & Investment Co. grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 7.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 113,798 shares of the biopharmaceutical company’s stock after acquiring an additional 7,650 shares during the quarter. Community Trust & Investment Co.’s holdings in Pfizer were worth $3,293,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Private Advisor Group LLC grew its holdings in shares of Pfizer by 15.4% during the third quarter. Private Advisor Group LLC now owns 849,585 shares of the biopharmaceutical company’s stock valued at $24,587,000 after buying an additional 113,623 shares in the last quarter. Tempus Wealth Planning LLC grew its holdings in shares of Pfizer by 3.4% during the third quarter. Tempus Wealth Planning LLC now owns 18,301 shares of the biopharmaceutical company’s stock valued at $530,000 after buying an additional 604 shares in the last quarter. Westhampton Capital LLC grew its holdings in shares of Pfizer by 31.2% during the third quarter. Westhampton Capital LLC now owns 41,678 shares of the biopharmaceutical company’s stock valued at $1,206,000 after buying an additional 9,900 shares in the last quarter. Symphony Financial Ltd. Co. grew its holdings in shares of Pfizer by 19.1% during the third quarter. Symphony Financial Ltd. Co. now owns 41,106 shares of the biopharmaceutical company’s stock valued at $1,181,000 after buying an additional 6,586 shares in the last quarter. Finally, Waldron Private Wealth LLC grew its holdings in shares of Pfizer by 5.2% during the third quarter. Waldron Private Wealth LLC now owns 62,399 shares of the biopharmaceutical company’s stock valued at $1,806,000 after buying an additional 3,059 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $28.85 on Wednesday. The company has a market capitalization of $163.45 billion, a PE ratio of -480.75, a PEG ratio of 1.02 and a beta of 0.67. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock’s fifty day simple moving average is $29.07 and its 200 day simple moving average is $28.48.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the business posted $0.67 EPS. On average, research analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.82%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is currently -2,800.00%.

Analysts Set New Price Targets

A number of brokerages have commented on PFE. Barclays boosted their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Thursday, October 3rd. Finally, UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.91.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.